Trastuzumab

General

Dosage Forms & Strengths

injection, powder for reconstitution

  • 150mg/single-dose vial (Herceptin)
  • 420mg/multi-dose vial (Herceptin, Ogivri)

Biosimilar to Herceptin

  • Ogivri (trastuzumab-dkst)

Breast Cancer

Adjuvant treatment

  • Herceptin, Ogivri
  • Indicated for adjuvant treatment of HER-2 overexpressing breast cancer
  • See also Administration
  • During and following paclitaxel, docetaxel, or docetaxel/carboplatin
    • 4 mg/kg IV over 90 min, THEN
    • 2 mg/kg IV over 30 min qWeek during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin)
    • One week following the last weekly dose, administer at 6 mg/kg as an IV over 30−90 min q3Weeks
    • Administer according to doses and schedules for a total of 52 weeks
  • As a single agent within 3 weeks following completion of multi-modality, anthracycline-based chemotherapy regimens
    • 8 mg/kg IV over 90 min, THEN
    • 6 mg/kg as an IV over 30−90 min q3Weeks
    • Administer according to doses and schedules for a total of 52 weeks
    • Extending adjuvant treatment beyond one year not recommended

Metastatic breast cancer

  • Treat as a single agent or in combination with paclitaxel
  • 4 mg/kg IV over 90 min, THEN
  • 2 mg/kg IV over 30 min, qWeek, continue until disease progression

Gastric Cancer

Herceptin, Ogivri

Indicated for treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

See also Administration

Administered in combination with cisplatin and capecitabine or 5-fluorouracil who have not received prior treatment for metastatic disease

8 mg/kg IV; infuse IV over 90 min, THEN

6 mg/kg IV q3wk; infuse IV over 30-90 min, continue until disease progression

Dosage Modifications

Modifications required for serious adverse events, including hypersensitivity reaction (anaphylaxis), infusion reactions (fatalities), decreased left ventricular function, and pulmonary events (ARDS)

Infusion Reactions

  • Decrease infusion rate for mild-moderate infusion reactions
  • Interrupt infusion if dyspnea or clinically significant hypotension
  • Strongly consider permanent discontinuation if severe and life-threatening infusion reactions

Cardiomyopathy

  • Assess LVEF prior to initiation and frequently during treatment
  • Withhold for at least 4 weeks
    • 16% absolute decrease in LVEF from pre-treatment values
    • LVEF below institutional limits of normal and ≥10% absolute decrease in LVEF from pretreatment values
    • Resume drug if, within 4-8 weeks, the LVEF returns to normal and absolute decrease from baseline is ≤15%
    • Permanently discontinue for a persistent (>8 weeks) LVEF decline or for suspension of drug on >3 occasions for cardiomyopathy

Dosing Considerations

Do not substitute ado-trastuzumab emtansine (Kadcyla) for or with trastuzumab (Herceptin); see Black Box Warnings

Patient selection is based on HER2 protein overexpression or HER2 gene amplification; assessment of HER2 protein overexpression and gene amplification should be performed using FDA-approved tests specific for breast or gastric cancers by laboratories with demonstrated proficiency; FDA-approved tests for detection of HER2 protein overexpression and HER2 gene amplification is available at: http://www.fda.gov/CompanionDiagnostics

See also Administration

Pancreatic Cancer (Orphan)

Herceptin only

Indicated for the treatment of patients with pancreatic cancer that overexpress p185HER2

Orphan indication sponsor

  • Genentech, Inc; 1 DNA Way; South San Francisco, CA 94080-4990

    Adverse Effects:

    >10% (Metastatic breast cancer)

    Pain (47%)

    Asthenia (42%)

    Fever (36%)

    Nausea (33%)

    Chills (32%)

    Cough (26%)

    Headache (26%)

    Diarrhea (25%)

    Vomiting (23%)

    Abdominal pain (22%)

    Back pain (22%)

    Dyspnea (22%)

    Infection (20%)

    Rash (18%)

    Anorexia (14%)

    Insomnia (14%)

    Dizziness (13%)

    1-10% (Adjuvant Breast Treatment)

    Headache (10%)

    Nasopharyngitis (8%)

    Diarrhea (7%)

    Nausea (6%)

    Pyrexia (6%)

    Peripheral edema (5%)

    Back pain (5%)

    Chills (5%)

    Asthenia (4.5%)

    Myalgia (4%)

    Hypertension (4%)

    Dizziness (4%)

    Influenza (4%)

    Rash (4%)

    Vomiting (3.5%)

    Bone pain (3%)

    UTI (3%)

    Administration:

    IV Incompatibilities

    Dextrose solutions

    Not to be mixed with other drugs

    IV Preparation

    420 mg multiple-dose vial

    • Reconstitute powder with 20 mL of supplied diluent (bacteriostatic water for injection [BWFI]; contains 1.1% benzyl alcohol as a preservative)
    • If patient has known hypersensitivity to benzyl alcohol, drug may be reconstituted with sterile water for injection (SWI), but use SWI-reconstituted drug immediately
    • Reconstituted vial yields 21 mg/mL
    • Slowly inject 20 mL of diluent into vial; stream of diluent should be directed into the lyophilized cake
    • Do not shake; swirl vial gently to aid reconstitution
    • Slight foaming of the product may be present upon reconstitution; allow vial to stand undisturbed for ~5 minutes
    • Solution should be free of visible particulates; appear clear to slightly opalescent and colorless to pale yellow
    • See also Storage

    150 mg single-dose vial

    • Reconstitute with 7.4 mL of Sterile Water for Injection (SWFI) (not supplied) to yield a solution containing 21 mg/mL trastuzumab
    • Do not shake; swirl vial gently to aid reconstitution
    • Slight foaming of the product may be present upon reconstitution; allow vial to stand undisturbed for ~5 minutes
    • Solution should be free of visible particulates; appear clear to slightly opalescent and colorless to pale yellow

    Further dilution

    • Withdraw calculated dose from reconstituted vial and add to a polyvinylchloride- or polyethylene-bag containing 250 mL 0.9% NaCl
    • Gently invert the bag to mix the solution

    IV Administration

    Not for IV push or bolus administration

    Administer initial IV infusion over 90 min

    Subsequent weekly IV infusions may be administered over 30 min if prior infusions are well tolerated

    Missed dose ≤1 week

    • Usual maintenance dose (weekly schedule: 2 mg/kg; three-weekly schedule: 6 mg/kg) should be administered as soon as possible
    • Do not wait until next planned cycle
    • Subsequent maintenance doses should be administered 7 days or 21 days later according to qWeek or q3Weeks schedule, respectively

    Missed dose >1 week

    • Reload dose (weekly schedule: 4 mg/kg; three-weekly schedule: 8 mg/kg) over ~90 min, as soon as possible
    • Subsequent maintenance doses (weekly schedule: 2 mg/kg; three-weekly schedule 6 mg/kg) should be administered 7 days or 21 days later according to qWeek or q3Weeks schedule, respectively
General
New European HTN Guidelines Hit Hard With Initial Therapy, Keep ‘High-Normal’ Label

he new European guidelines for diagnosing and managing arterial hypertension maintain the previous classification system based on blood pressure  (BP) levels but recommends a harder-hitting initial treatment approach compared to the previous version, released in 2013. The 2018 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines document …

General
Splenic Abscess Treatment & Management

Once the diagnosis of a splenic abscess has been made, the patient must be admitted to the hospital and treated. Treatment depends on the patient’s overall condition, comorbidities, and primary disorder (if any), as well as the size and topography of the abscess. [22] Empiric broad-spectrum antibiotic therapy has a primary …

General
How to Use Condoms Safely

  If you’re looking for protection against pregnancy and sexually transmitted infections (STIs) without a prescription, condoms may be a good option to explore. They’re discrete, relatively inexpensive, and don’t involve any synthetic hormones. Condoms are also readily available at your nearest convenience or drug store. What are the safest …

Show Buttons
Hide Buttons